Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through our Condensomics platform, our goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. We harness droplet microfluidic approaches and cellular platforms to characterize condensates with unprecedented scale and precision, resulting in the mapping of condensates and their modulation, in molecular detail. Our proprietary datasets feed in to algorithms that we use for target discovery, target validation and drug design.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $50M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 26.06.2021 | Lifeforce ... | lifeforcec... |
| 09.08.2022 | Taiho Vent... | taihoventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.06.2022 | Series A | $50M | - |
Mentions in press and media 9
| Date | Title | Description |
| 10.09.2026 | Transition Bio Partners with the Little Warrior Foundation | - |
| 10.06.2023 | Transition Bio Closes $50M Series A Financing | CAMBRIDGE, MA, Transition Bio, Inc., a microfluidics-driven drug discovery platform, announced its $50 million Series A financing, led by Northpond Ventures. >> Click here for more funding data on Transition Bio >> To export... |
| 06.06.2022 | Why the fates of PE and VC-backed companies may diverge in 2022 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. We’ve been hearing it for a few months now: There are rough times ahead for private companies. Pa... |
| 05.06.2022 | Transition Bio Closes $50 Million Series A Financing to Accelerate Biomolecular Condensate Drug Discovery | Transition Bio, Inc., a microfluidics-driven drug discovery platform company using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates, announced its $50 million Series A financing, led by Nor... |
| 02.06.2022 | Transition Bio Closes $50M Series A Financing | Transition Bio, Inc., a Cambridge, MA- and Cambridge, UK-based provider of a microfluidics-driven drug discovery platform using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates, raised $50m... |
| 01.12.2020 | Transition Bio, Inc. closes seed financing and launches company | Transition Bio, Inc. closes seed financing and launches company 01-12-2020 CAMBRIDGE, Mass. & CAMBRIDGE, England--Transition Bio, Inc. was recently formed, funded and launched with the focused objective to build the best and first-in-cl... |
| 01.12.2020 | Transition Bio, Inc. closes seed financing and launches company | CAMBRIDGE, Mass. & CAMBRIDGE, England--Transition Bio, Inc. was recently formed, funded and launched with the focused objective to build the best and first-in-class technological capabilities required to evaluate and advance the novel a... |
| - | StartUPDATES: New developments from healthcare startups | Carrum Health and Employer Health Innovation Roundtable (EHIR) released a survey that found employers’ desire to drive down healthcare expenditures and improve quality will likely lead to an increase in usage of Centers of Excellence (COE).... |
| - | Transition Bio | “Home - Transition Bio” |